Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab

Atopic dermatitis (AD) is a chronic, multifactorial, inflammatory skin disease which can have a negative impact on the quality of life (QoL). The moderate-to-severe forms frequently require systemic treatment. Dupilumab is a human monoclonal antibody directed against the alpha subunit of the IL-4 receptor. It has been the first biologic drug that approved for the treatment of moderate to severe AD.